Onconetix Inc (ONCO) USD0.00001

Sell:$4.47Buy:$4.85$0.20 (4.12%)

Prices delayed by at least 15 minutes
Sell:$4.47
Buy:$4.85
Change:$0.20 (4.12%)
Deal now
Prices delayed by at least 15 minutes
Sell:$4.47
Buy:$4.85
Change:$0.20 (4.12%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

Key people

Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Andrew J. Oakley
Director
Thomas Meier
Independent Director
Timothy R. Ramdeen
Independent Director
Ajit Singh
Independent Director
Simon Tarsh
Independent Director
Click to see more

Key facts

  • EPIC
    ONCO
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US68237Q2030
  • Market cap
    $2.53m
  • Employees
    5
  • Shares in issue
    522,015.10
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.